[Federal Register: October 18, 2001 (Volume 66, Number 202)]
[Notices]
[Page 52924-52925]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr18oc01-73]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Anti-Infective Drugs Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Anti-Infective Drugs Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on November 7, 2001, from 8
a.m. to 5 p.m.
Location: Holiday Inn, Kennedy Ballroom, 8777 Georgia Ave., Silver
Spring, MD.
Contact: Thomas H. Perez, Center for Drug Evaluation and Research
(HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville,
MD 20857, 301-827-6758, e-mail: PerezT@cder.fda.gov, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 12530. Please call the Information Line for
up-to-date information on this meeting.
Agenda: The committee will consider the safety and efficacy of a
new drug application (NDA) 50-710, Pfizer, Inc., for 1-day and 3-day
dosing regimens of azithromycin suspension for the treatment of otitis
media.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by October 30,
2001. Oral presentations from the public will be scheduled between
approximately 1 p.m. and 2 p.m. Time allotted for each presentation may
be limited. Those desiring to make formal oral presentations should
notify the contact person before October 30, 2001, and submit a brief
statement of the general
[[Page 52925]]
nature of the evidence or arguments they wish to present, the names and
addresses of proposed participants, and an indication of the
approximate time requested to make their presentation.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: October 11, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 01-26276 Filed 10-17-01; 8:45 am]
BILLING CODE 4160-01-S